Topic summary

Naming conventions for research peptides and the confusion they cause

Compounds › Other compounds custom synthesis mislabelling research use only needs a source

This is a generated summary. It shows the 5 most-liked posts from a topic of 26, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

NicolaidesTL3Regular9 May 2026#2

Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that actually matters. A supplier's certificate stating the name is not verification.

19 likes 3mo

a.villalobosTL2 Moderator30 May 2026#9

Distinguishing marketed research compounds from true chemical synthesis: some online suppliers sell compounds that are genuinely novel and difficult to obtain elsewhere. Others repackage standard compounds. Verifying what you are buying requires careful documentation review.

18 likes 2mo

RodriguesTL3Regular4 Jun 2026#11

Coming back to post #9, because the follow-up matters more than the original answer.

When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and reasoning from theory is not a substitute. That is not a reason for shame; it is the honest epistemic position.

25 likes 2mo

IHollingworthTL2Member13 Jun 2026#15

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

18 likes 1mo

pe.onwukaTL2 Moderator6 Jul 2026#26

26 likes 22d

Read the full topic (26 posts)

This topic was referenced in

Revisiting: Melanocortin agonists: mechanism and the documented adverse profileCompounds › Other compounds · 141 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Coming back to: When "no data" is the complete and final answer Compounds › Other compounds research use only needs a source custom synthesis When "no data" is the complete and final answer I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…	+77	82	12k	11mo
AOD-9604 and the fragment hypothesis, revisited Compounds › Other compounds mislabelling research use only custom synthesis needs a source Posting this under the heading it deserves: AOD-9604 and the fragment hypothesis, revisited Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SUSTAIN 6 ( N Engl J Med…	+40	44	2.8k	6mo
Second pass at: How to research a compound with no human data without deceiving yourself Compounds › Other compounds research use only custom synthesis needs a source mislabelling Second pass at: How to research a compound with no human data without deceiving yourself Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med ,…	+64	71	2.5k	13mo
Coming back to: Reading a supplier's product description as a marketing document Compounds › Other compounds needs a source custom synthesis research use only mislabelling Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…	+35	39	688	5mo
Compounds this community declines to help with, and why — does this still hold? Compounds › Other compounds custom synthesis research use only mislabelling Compounds this community declines to help with, and why — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med ,…	+3	7	26k	7h

Related topics — sharing the tags custom synthesis, mislabelling, research use only

Topic	Participants	Replies	Views	Activity
AOD-9604 and the fragment hypothesis, revisited Compounds › Other compounds mislabelling research use only custom synthesis needs a source Posting this under the heading it deserves: AOD-9604 and the fragment hypothesis, revisited Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SUSTAIN 6 ( N Engl J Med…	+40	44	2.8k	6mo
Why a preprint's supplementary material is often the best part Evidence › Preprints needs a source risk of bias preprint effect size Why a preprint's supplementary material is often the best part I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: SUSTAIN 6 ( N Engl J Med , 2016). Please…	+38	42	863	22mo
Analytical identity of BPC-157: a 15-mer with a simple mass Compounds › Repair & healing peptides BPC-157 observational data needs a source preprint Analytical identity of BPC-157: a 15-mer with a simple mass Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024) with STEP 2 (…	+3	7	5.2k	10mo
About the Other compounds category Compounds › Other compounds research use only custom synthesis needs a source Pinned Wiki Closed Anything not covered by a dedicated subcategory, including research-use-only material with no human data. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+8	12	51k	7mo
Oral versus injected administration claims for BPC-157 Compounds › Repair & healing peptides BPC-157 observational data preprint TB-500 Oral versus injected administration claims for BPC-157 — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think…	+20	24	47k	4mo